TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data

from the beginning

TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data

IMPORTANT NOTICE

1. Efficacy and safety results from the randomized, double-blind, placebo-controlled phase 2b trial of TYK2 inhibitor NDI-034858* in moderate-to-severe psoriasis

Mechanism of action of NDI-034858(TAK-279)

Study design: NCT04999839(US, Canada)

Study disposition

Demographics and baseline disease characteristics

Patients achieving PASI 75, 90 or 100 at Week 12

Representative PASI 100 response with TAK-279 30 mg QD

Patients achieving PGA 0/1 or PGA 0 at Week 12

Safety summary

Common terminology criteria for adverse events Grade 3

Conclusions

ANTICIPATED NEXT STEPS FOR TAK-279

2. Q&A Session

• Q&A Session1

• Q&A Session2

• Q&A Session3

• Q&A Session4

• Q&A Session5

• Q&A Session6

• Q&A Session7

APPENDIX

@

@

@

@

@

@